These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20822713)

  • 1. Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica.
    Pulsatelli L; Peri G; Macchioni P; Boiardi L; Salvarani C; Cantini F; Mantovani A; Meliconi R
    Clin Exp Rheumatol; 2010; 28(5):756-8. PubMed ID: 20822713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
    van Sleen Y; Boots AMH; Abdulahad WH; Bijzet J; Sandovici M; van der Geest KSM; Brouwer E
    Rheumatology (Oxford); 2020 Jan; 59(1):176-184. PubMed ID: 31292652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
    Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
    J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
    Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
    Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.
    Ramirez GA; Rovere-Querini P; Blasi M; Sartorelli S; Di Chio MC; Baldini M; De Lorenzo R; Bozzolo EP; Leone R; Mantovani A; Manfredi AA; Tombetti E
    Front Immunol; 2019; 10():1135. PubMed ID: 31191526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
    Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
    Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
    Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
    Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
    Wang H; Wang K; Wang C; Zhong X; Qiu W; Hu X
    Mult Scler; 2013 Jun; 19(7):926-31. PubMed ID: 23012252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
    Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia.
    Baldini M; Maugeri N; Ramirez GA; Giacomassi C; Castiglioni A; Prieto-González S; Corbera-Bellalta M; Di Comite G; Papa I; Dell'antonio G; Ammirati E; Cuccovillo I; Vecchio V; Mantovani A; Rovere-Querini P; Sabbadini MG; Cid MC; Manfredi AA
    Arthritis Rheum; 2012 Mar; 64(3):854-65. PubMed ID: 21989653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyalgia rheumatica can recur years after discontinuation of corticosteroid therapy.
    Docken WP
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S25-7. PubMed ID: 19646342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia.
    Kao SJ; Yang HW; Tsao SM; Cheng CW; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
    Clin Chem Lab Med; 2013 Apr; 51(4):907-13. PubMed ID: 23152412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica.
    Boiardi L; Casali B; Farnetti E; Pipitone N; Nicoli D; Cantini F; Macchioni P; Bajocchi G; Catanoso MG; Pulsatelli L; Consonni D; Salvarani C
    J Rheumatol; 2006 Apr; 33(4):703-8. PubMed ID: 16583473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.
    Infante M; Allavena P; Garlanda C; Nebuloni M; Morenghi E; Rahal D; Roncalli M; Cavuto S; Pesce S; Monari M; Valaperta S; Montanelli A; Solomon D; Bottoni E; Errico V; Voulaz E; Bossi M; Chiesa G; Passera E; Mantovani A; Alloisio M
    Int J Cancer; 2016 Feb; 138(4):983-91. PubMed ID: 26348770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis.
    Meyer O; Nicaise P; Moreau S; de Bandt M; Palazzo E; Hayem G; Chazerain P; Labarre C; Kahn MF
    Rev Rhum Engl Ed; 1996 Apr; 63(4):241-7. PubMed ID: 8738442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
    Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
    Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating RANKL/OPG in polymyalgia rheumatica.
    Pulsatelli L; Dolzani P; Silvestri T; Boiardi L; Salvarani C; Macchioni P; Facchini A; Meliconi R
    Clin Exp Rheumatol; 2007; 25(4):621-3. PubMed ID: 17888221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
    Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
    Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pentraxin 3 in patients with chronic heart failure.
    Kotooka N; Inoue T; Aoki S; Anan M; Komoda H; Node K
    Int J Cardiol; 2008 Oct; 130(1):19-22. PubMed ID: 18045709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
    Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
    Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.